Showing 13 to 18 of 18 results
Full-Spectrum Cannabis Drug Shows Promise in Autism Treatment
Ajna BioSciences, in collaboration with Charlotte's Web and British American Tobacco, is developing AJA001, a full-spectrum hemp-derived cannabinoid drug for autism spectrum disorder (ASD), which successfully completed Phase 1 trials demonstrating safety and efficacy, and plans to launch Phase 2 tri...
Full-Spectrum Cannabis Drug Shows Promise in Autism Treatment
Ajna BioSciences, in collaboration with Charlotte's Web and British American Tobacco, is developing AJA001, a full-spectrum hemp-derived cannabinoid drug for autism spectrum disorder (ASD), which successfully completed Phase 1 trials demonstrating safety and efficacy, and plans to launch Phase 2 tri...
Progress
44% Bias Score
FDA Approves Renal Denervation for Treatment-Resistant Hypertension
The FDA recently approved renal denervation, a minimally invasive procedure to treat hypertension by disrupting overactive kidney nerves, offering a new option for patients whose blood pressure remains high despite medication and lifestyle changes.
FDA Approves Renal Denervation for Treatment-Resistant Hypertension
The FDA recently approved renal denervation, a minimally invasive procedure to treat hypertension by disrupting overactive kidney nerves, offering a new option for patients whose blood pressure remains high despite medication and lifestyle changes.
Progress
32% Bias Score
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
Progress
44% Bias Score
Renal Denervation Offers Hope for Treatment-Resistant Hypertension
Doctors successfully controlled Michael Garity's dangerously high blood pressure by ablating nerves in his kidneys using renal denervation, a new treatment approved by the FDA that disrupts overactive kidney nerves, offering hope for patients with treatment-resistant hypertension.
Renal Denervation Offers Hope for Treatment-Resistant Hypertension
Doctors successfully controlled Michael Garity's dangerously high blood pressure by ablating nerves in his kidneys using renal denervation, a new treatment approved by the FDA that disrupts overactive kidney nerves, offering hope for patients with treatment-resistant hypertension.
Progress
16% Bias Score
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
Progress
36% Bias Score
FDA Clears Spinal Stimulator Offering Hope for Spinal Cord Injury Patients
The FDA recently approved ARC-EX Therapy, a non-invasive spinal stimulator showing significant promise in improving hand function and reducing pain for patients with spinal cord injuries, based on results from the Up-LIFT clinical trial where 72% of participants with cervical injuries saw improvemen...
FDA Clears Spinal Stimulator Offering Hope for Spinal Cord Injury Patients
The FDA recently approved ARC-EX Therapy, a non-invasive spinal stimulator showing significant promise in improving hand function and reducing pain for patients with spinal cord injuries, based on results from the Up-LIFT clinical trial where 72% of participants with cervical injuries saw improvemen...
Progress
36% Bias Score
Showing 13 to 18 of 18 results